Exchange Traded Concepts’s Intellia Therapeutics NTLA Stock Holding History

Exchange Traded Concepts’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,661	Closed	-$433K	–	1310
2021 Q4	$433K	Buy	+3,661	New	+$459K	0.01%	713
2021 Q1	–	Sell	-5,509	Closed	-$300K	–	1124
2020 Q4	$300K	Sell	5,509 -23,530	-81%	-$854K	0.01%	588
2020 Q3	$577K	Buy	29,039 +14,997	+107%	+$313K	0.03%	273
2020 Q2	$295K	Buy	14,042 +6,516	+87%	+$111K	0.05%	386
2020 Q1	$92K	Buy	7,526 +3,741	+99%	+$50.4K	0.05%	264
2019 Q4	$56K	Buy	+3,785	New	+$52.7K	0.01%	271

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Exchange Traded Concepts's NTLA Position: Q1 2022 in Review

Exchange Traded Concepts sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 3,661 shares — an estimated $433K sold.

Exchange Traded Concepts first reported a position in NTLA in Q4 2019 and held it in 6 quarters. The position peaked at $577K in Q3 2020. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

Exchange Traded Concepts reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
Exchange Traded Concepts sold 3,661 Intellia Therapeutics shares in Q1 2022, an estimated $433K.
Exchange Traded Concepts first reported a position in Intellia Therapeutics in Q4 2019 and held it in 6 quarters.
Exchange Traded Concepts's Intellia Therapeutics position peaked at $577K in Q3 2020.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Exchange Traded Concepts's 13F filing for Q1 2022, filed 26 Apr 2022.